Browse
Submit Data
Databases
API
Help

Dataset Information

26 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

ABSTRACT: This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

DISEASE(S): Endometrial Cancer,Carcinoma,Small Cell Lung Cancer,Colorectal Cancer,Advanced Solid Tumors,Cervical Carcinoma,Urothelial Carcinoma,Endometrial Neoplasms,Breast Neoplasms,Pancreatic Carcinoma,Lung Neoplasms,Gastric Or Gastroesophageal Junction Adenocarcinoma,Colorectal Carcinoma,Melanoma (excluding Uveal Melanoma),Squamous Cell Carcinoma Of The Head And Neck,Gastric Cancer,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Renal Cell Carcinoma,Pancreatic Neoplasms,Non-small Cell Lung Carcinoma,Hepatocellular Carcinoma,Nasopharyngeal Carcinoma,Breast Carcinoma That Is Estrogen Receptor, Progesterone Receptor, And Her2 Negative,Sarcoma,Cervical Cancer,Melanoma,Small Cell Lung Carcinoma,Bladder Cancer,Undifferentiated Pleomorphic Sarcoma,Histiocytoma, Malignant Fibrous,Pancreatic Cancer,Squamous Cell Carcinoma Of Head And Neck,Non-small Cell Lung Cancer,Head And Neck Cancer,Endometrial Carcinoma

PROVIDER: 2290382 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors

Project description:This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

| 2272339 | ecrin-mdr-crc

A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Project description:This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

| 2297842 | ecrin-mdr-crc

BMS_IM125001_WB_study

Project description:The goal of this study is to define the molecular signatures of prednisolone and BMS-791826 in normal healthy volunteers. IM125001 (NCT03198013) is a phase I, placebo-controlled, double-blind, ascending single and multiple oral dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of bms-791826 and to assess its marker specific pharmacodynamics in relation to prednisolone in healthy males, sponsored by Bristol-Myers Squibb.

2018-02-06 | GSE110161 | GEO

A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Project description:This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.

| 2348822 | ecrin-mdr-crc

Recombination map of male germline cell for a single Holstein bull

Project description:Using Illumina® BovineHD Genotyping BeadChip assay, we applied single sperms genotyping from one single Holstein bull to preliminarily describe its recombination map. We received 56 single sperms with qualified genotype information and totally detected 1,526 autosomal crossovers.

2018-05-13 | GSE99620 | GEO

Biopsies from advanced melanoma before and/or after treatment with nivolumab

Project description:Expression profiling of tumor samples obtained during CA209-038 (ClinicalTrials.gov Identifier: NCT01621490). The purpose of this study is to evaluate pharmacodynamic changes of nivolumab and nivolumab in combination with ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced). Samples are rumor core needle biopsies obtained at trial enrolment (i.e. Screen) and/or at Cycle 1 Day 29 (i.e.Week 4) from Subjects With Advanced Melanoma (Unresectable or Metastatic) treated with nivolumab (BMS-936558,MDX-1106) 3 mg/kg solution intravenously every 2 weeks on Bristol-Myers Squibb clinical trial protocol CA209-038 Part 1 . Cohort 2 patients have progressed on anti-CTLA4 (ipilimumab) monoclonal antibody therapy. Values are from an interim lock of the trial data in July 2014. Best overall response (BOR) was defined using RECIST 1.1 criteria: tumor assessments between date of first dose and the date of first objectively documented progression, or the date of non-missing subsequent anti-cancer therapy (whichever occurs first) were used to derive BOR. MPCT is Maximum reduction in tumor size (index lesions only) up to first progression, and is the value typically shown on a waterfall plot.

2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress

A Study of a Personalized Neoantigen Cancer Vaccine

Project description:The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.

| 2281724 | ecrin-mdr-crc

CD4+ Th immunogenicity of Ascaris spp.

Project description:Application of a reconstituted in vitro system to define the CD4+ Th immunogenicity of complex antigenic mixtures.

2020-03-04 | PXD015924 | Pride

CD4+ Th immunogenicity of Ascaris spp.

Project description:Application of a reconstituted in vitro system to define the CD4+ Th immunogenicity of complex antigenic mixtures.

2020-03-04 | PXD015012 | Pride

Proteomics of Human Cervical Mucus Plugs

Project description:Preterm birth is a leading cause of neonatal mortality and lacks an effective therapy. Ascending microbial infections from the lower genital tract lead to infection of the placenta, amniotic fluid and fetus causing preterm birth or stillbirth. Directly in the path of an ascending infection is the cervical mucus plug (CMP), a dense mucoid structure in the cervical canal with potential antimicrobial properties. In this study, we aimed to define the components of CMP responsible for antimicrobial activity against a common lower genital tract organism associated with preterm birth and stillbirths, namely Group B Streptococcus (GBS). Using a quantitative proteomic approach, we identified antimicrobial factors in CMPs that were collected from healthy human pregnancies. This study aims to provide new insight into how the human CMP may limit ascending bacterial infection.

2018-02-09 | PXD008600 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data